You Have Four Days to Tell the DEA the Difference Between Kratom and 7-OH

If you use kratom and haven’t been following the 7-OH fight closely, here’s the part that matters this week: the window to say something about it closes September 10.

The DEA isn’t proposing to ban kratom. It’s proposing to draw a line inside it, and where that line lands decides who’s still in business next month.

7-hydroxymitragynine, or 7-OH, is a compound that occurs naturally in kratom leaf at trace levels but can be concentrated in manufactured tablets and extracts to a much higher, more opioid-like potency. The DEA’s proposed temporary scheduling would place products above a 0.05% dry-weight threshold into Schedule I — the same category as heroin — while leaving natural kratom leaf below that threshold untouched. Assistant Secretary for Health Brian Christine’s office reopened the comment period after the original 30-day window closed July 31 with more than 32,000 submissions already filed — a volume that tells you this isn’t a niche regulatory question to the people who use these products.

Mac Haddow of the American Kratom Association, which supports kratom leaf but backs scheduling the boosted 7-OH products, told Pain News Network he expects the DEA to take its time rather than move immediately: “They (DEA) could have a 7-OH ban right now. I think it more likely…that they’ll give it time to be evaluated.” Jackie Subeck of the 7-HOPE Alliance made the same request from the opposite side of the product debate, asking for “consultation with scientific advisors, review of the available literature, coordination with affected stakeholders” before anything permanent happens. Two groups that disagree about which products should survive agree on one thing: a threshold this consequential shouldn’t get set without people weighing in first. Related synthetic kratom derivatives — mitragynine pseudoindoxyl, MGM-15, and MGM-16 — already went Schedule I on August 26, so the direction of travel here isn’t in doubt. What’s still open is where the line falls for everything else.

If kratom or 7-OH is part of how you manage pain, opioid withdrawal, or your own recovery, the comment period is the one part of this process where your actual experience — dose, product type, what happened when you couldn’t get it — carries as much legal weight as an industry lobbyist’s. It closes September 10. After that, the line gets drawn without you.